PSTV Logo

Plus Therapeutics, Inc. (PSTV) 

NASDAQ
Market Cap
$6.37M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
265 of 959
Rank in Industry
161 of 550

Largest Insider Buys in Sector

PSTV Stock Price History Chart

PSTV Stock Performance

About Plus Therapeutics, Inc.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori …

Insider Activity of Plus Therapeutics, Inc.

Over the last 12 months, insiders at Plus Therapeutics, Inc. have bought $151,609 and sold $0 worth of Plus Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Plus Therapeutics, Inc. have bought $89,709 and sold $4,525 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Petersen Greg (director) — $125,626. Hawkins Richard J (director) — $49,016. HEDRICK MARC H (Chief Executive Officer) — $34,839.

The last purchase of 4,000 shares for transaction amount of $5,996 was made by Hawkins Richard J (director) on 2024‑09‑13.

List of Insider Buy and Sell Transactions, Plus Therapeutics, Inc.

2024-09-13Purchasedirector
4,000
0.0687%
$1.50$5,996-9.80%
2024-09-12Purchasedirector
6,285
0.1009%
$1.35$8,512-6.29%
2024-09-11Purchasedirector
12,500
0.2271%
$1.35$16,8750.00%
2024-09-11Purchasedirector
5,000
0.0899%
$1.34$6,6810.00%
2024-09-10PurchaseChief Executive Officer
8,000
0.1324%
$1.23$9,839+6.35%
2024-09-10PurchaseChief Financial Officer
4,098
0.0701%
$1.27$5,204+6.35%
2024-05-08Purchasedirector
12,255
0.2576%
$2.04$25,000-36.12%
2024-05-08Purchasedirector
4,167
0.0876%
$2.04$8,501-36.12%
2024-05-08Purchasedirector
9,804
0.206%
$2.04$20,000-36.12%
2024-05-08PurchaseChief Executive Officer
12,255
0.2576%
$2.04$25,000-36.12%
2024-05-08PurchaseChief Financial Officer
4,902
0.103%
$2.04$10,000-36.12%
2024-05-08Purchasedirector
4,902
0.103%
$2.04$10,000-36.12%
2023-11-20SaleChief Executive Officer
2,068
0.0487%
$1.96$4,053+1.66%
2023-11-16Purchasedirector
1,000
0.02%
$1.95$1,950-16.44%
2023-11-15Purchasedirector
1,000
0.0206%
$1.77$1,770-2.14%
2023-11-13Purchasedirector
4,000
0.086%
$1.43$5,720+24.83%
2023-11-10Purchasedirector
2,000
0.0452%
$1.45$2,900+30.96%
2023-11-09Purchasedirector
4,199
0.0971%
$1.59$6,676+23.32%
2023-11-08Purchasedirector
5,000
0.1147%
$1.65$8,250+15.41%
2023-11-07Purchasedirector
6,000
0.1303%
$1.64$9,840+11.21%

Insider Historical Profitability

<0.0001%
Petersen Gregdirector
48921
0.8297%
$1.0870<0.0001%
Lenk Robert Pdirector
29327
0.4974%
$1.08111<0.0001%
Clowes Howarddirector
26497
0.4494%
$1.0870<0.0001%
HEDRICK MARC HChief Executive Officer
20425
0.3464%
$1.08282<0.0001%
Hawkins Richard Jdirector
15188
0.2576%
$1.0840<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.